Market Cap | 2.18M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -32.28M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -22.00% |
Sales | 2.16M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -63.00% |
Dividend | N/A | Price/Book | 0.07 | EPS next 5Y | - | 52W High Chg | -96.00% |
Recommedations | - | Quick Ratio | 0.04 | Shares Outstanding | 2.59M | 52W Low Chg | 4.00% |
Insider Own | 1.91% | ROA | -25.61% | Shares Float | 782.54K | Beta | 1.47 |
Inst Own | 0.74% | ROE | -279.79% | Shares Shorted/Prior | 26.74K/76.63K | Price | 0.56 |
Gross Margin | 5.16% | Profit Margin | - | Avg. Volume | 225,004 | Target Price | - |
Oper. Margin | -521.92% | Earnings Date | - | Volume | 230,295 | Change | -7.75% |
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products for medicinal use worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.